PE20020220A1 - Compuestos de nitrilo de dipeptido como inhibidores de catepsina k - Google Patents
Compuestos de nitrilo de dipeptido como inhibidores de catepsina kInfo
- Publication number
- PE20020220A1 PE20020220A1 PE2001000139A PE2001000139A PE20020220A1 PE 20020220 A1 PE20020220 A1 PE 20020220A1 PE 2001000139 A PE2001000139 A PE 2001000139A PE 2001000139 A PE2001000139 A PE 2001000139A PE 20020220 A1 PE20020220 A1 PE 20020220A1
- Authority
- PE
- Peru
- Prior art keywords
- catepsin
- inhibitors
- carbamoil
- cyanomethyl
- het
- Prior art date
Links
- 108010016626 Dipeptides Proteins 0.000 title abstract 2
- -1 NITRILE COMPOUNDS Chemical class 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A COMPUESTOS DE NITRILO DE DIPEPTIDO DE FORMULA I, DONDE R1 Y R2 SON H, ALQUILO C1-C7 O JUNTO CON C FORMAN CICLOALQUILO C3-C8; HET ES HETEROCICLO CON N OPCIONALMENTE SUSTITUIDO, HET NO ES 4-PIRROL-1-ILO; HET PUEDE ESTAR EN LA POSICION 2 A 4 DEL FENILO. SON COMPUESTOS PREFERIDOS N-[1-(CIANOMETIL-CARBAMOIL)-CICLOHEXIL]-4-(PIPERAZIN-1-IL)-BENZAMIDA; N-[1-(CIANOMETIL-CARBAMOIL)-CICLOHEXIL]-4-(4-METIL-PIPERAZIN-1-IL)BENZAMIDA, N-[1-(CIANOMETIL-CARBAMOIL)-CICLOHEXIL]-4-(4-(1-PROPIL)-PIPERAZIN-1-IL]BENZAMIDA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. LOS COMPUESTOS I SON INHIBIDORES DE CATEPSINA K Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE INFLAMACION, ARTRITIS REUMATOIDE, OSTEOARTRITIS, OSTEOPOROSIS, TUMORES, ENFERMEDAD CORONARIA, ATEROSCLEROSIS; ENFERMEDADES AUTOINMUNES, RESPIRATORIAS, INFECCIOSAS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0003111.2A GB0003111D0 (en) | 2000-02-10 | 2000-02-10 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20020220A1 true PE20020220A1 (es) | 2002-03-25 |
Family
ID=9885359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001000139A PE20020220A1 (es) | 2000-02-10 | 2001-02-08 | Compuestos de nitrilo de dipeptido como inhibidores de catepsina k |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US6642239B2 (es) |
| EP (1) | EP1254124B1 (es) |
| JP (1) | JP3942895B2 (es) |
| KR (1) | KR100544553B1 (es) |
| CN (2) | CN1183122C (es) |
| AR (1) | AR029466A1 (es) |
| AT (1) | ATE402930T1 (es) |
| AU (1) | AU764334B2 (es) |
| BR (1) | BR0108118A (es) |
| CA (1) | CA2396158C (es) |
| CO (1) | CO5261578A1 (es) |
| CZ (1) | CZ20022721A3 (es) |
| DE (1) | DE60135087D1 (es) |
| ES (1) | ES2310177T3 (es) |
| GB (1) | GB0003111D0 (es) |
| HU (1) | HUP0300148A3 (es) |
| IL (1) | IL150406A0 (es) |
| MX (1) | MXPA02007768A (es) |
| MY (1) | MY122826A (es) |
| NO (1) | NO20023780D0 (es) |
| NZ (1) | NZ519940A (es) |
| PE (1) | PE20020220A1 (es) |
| PL (1) | PL200119B1 (es) |
| PT (1) | PT1254124E (es) |
| RU (2) | RU2265601C2 (es) |
| SK (1) | SK11462002A3 (es) |
| TR (1) | TR200201752T2 (es) |
| TW (1) | TWI258473B (es) |
| WO (1) | WO2001058886A1 (es) |
| ZA (1) | ZA200206218B (es) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9723407D0 (en) * | 1997-11-05 | 1998-01-07 | Ciba Geigy Ag | Organic compounds |
| CZ20013248A3 (cs) | 1999-03-15 | 2002-04-17 | Axys Pharmaceuticals, Inc. | Nové sloučeniny a prostředky jako inhibitory proteázy |
| GB0003111D0 (en) * | 2000-02-10 | 2000-03-29 | Novartis Ag | Organic compounds |
| US7148197B2 (en) * | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
| US7199102B2 (en) * | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| US7723303B2 (en) * | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| US7030116B2 (en) | 2000-12-22 | 2006-04-18 | Aventis Pharmaceuticals Inc. | Compounds and compositions as cathepsin inhibitors |
| WO2002051983A2 (en) | 2000-12-22 | 2002-07-04 | Axys Pharmaceuticals, Inc. | Novel compounds and compositions as cathepsin inhibitors |
| WO2003024924A1 (en) | 2001-09-14 | 2003-03-27 | Aventis Pharmaceuticals Inc. | Novel compounds and compositions as cathepsin inhibitors |
| WO2003042197A1 (en) | 2001-11-14 | 2003-05-22 | Aventis Pharmaceuticals Inc. | Oligopeptides and compositions containing them as cathepsin s inhibitors |
| NZ534583A (en) * | 2002-03-05 | 2006-11-30 | Axys Pharm Inc | Leucinamide derivatives suitable as cathepsin cysteine protease inhibitors |
| EP1569954A1 (en) * | 2002-12-05 | 2005-09-07 | Axys Pharmaceuticals, Inc. | Cyanomethyl derivatives as cysteine protease inhibitors |
| WO2005000800A1 (en) * | 2003-06-30 | 2005-01-06 | Merck Frosst Canada Ltd. | Cathepsin cysteine protease inhibitors |
| US20060281714A1 (en) * | 2003-07-21 | 2006-12-14 | Johann Zimmermann | Combinations of a cathepsin k inhibitor and a bisphosphonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss |
| MXPA06005635A (es) * | 2003-11-19 | 2006-08-17 | Novartis Ag | Uso de inhibidores de catepsina k para tratamiento de enfermedades de perdida osea severa. |
| CA2552739A1 (en) | 2004-01-08 | 2005-07-21 | Medivir Ab | Cysteine protease inhibitors |
| JP2008513479A (ja) * | 2004-09-16 | 2008-05-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | アテローム性動脈硬化症および他の病理を改善するためのｇ型ペプチドおよび他の薬剤 |
| EP1827472A4 (en) | 2004-12-06 | 2012-09-05 | Univ California | METHODS FOR IMPROVING THE STRUCTURE AND FUNCTION OF ARTERIOLES |
| GB0427380D0 (en) * | 2004-12-14 | 2005-01-19 | Novartis Ag | Organic compounds |
| WO2006076796A1 (en) * | 2005-01-19 | 2006-07-27 | Merck Frosst Canada Ltd. | Cathepsin k inhibitors and obesity |
| WO2006076797A1 (en) * | 2005-01-19 | 2006-07-27 | Merck Frosst Canada Ltd. | Cathepsin k inhibitors and atherosclerosis |
| US20080293639A1 (en) * | 2005-04-29 | 2008-11-27 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| GB0517637D0 (en) * | 2005-08-30 | 2005-10-05 | Novartis Ag | Organic compounds |
| EP2036920B1 (en) * | 2006-01-11 | 2011-05-18 | Seikagaku Corporation | Cycloalkylcarbonylamino acid ester derivative and process for producing the same |
| JP3975226B2 (ja) * | 2006-01-11 | 2007-09-12 | 生化学工業株式会社 | シクロアルキルカルボニルアミノ酸誘導体及びその製造方法 |
| JP4047365B2 (ja) | 2006-01-11 | 2008-02-13 | 生化学工業株式会社 | シクロアルカンカルボキサミド誘導体及びその製造方法 |
| AU2007253796A1 (en) * | 2006-05-22 | 2007-11-29 | Velcura Therapeutics, Inc. | Use of Cathepsin K antagonists in bone production |
| GB0614046D0 (en) | 2006-07-14 | 2006-08-23 | Amura Therapeutics Ltd | Compounds |
| GB0614044D0 (en) * | 2006-07-14 | 2006-08-23 | Amura Therapeutics Ltd | Compounds |
| GB0614053D0 (en) * | 2006-07-14 | 2006-08-23 | Amura Therapeutics Ltd | Compounds |
| EP2168600A1 (en) | 2007-06-08 | 2010-03-31 | Nippon Chemiphar Co., Ltd. | Therapeutic or prophylactic agent for cerebral aneurysm |
| BRPI0702541A2 (pt) | 2007-06-21 | 2009-02-10 | Petroleo Brasileiro Sa | processo de craqueamento catalÍtico para produÇço de diesel a partir de sementes de oleaginosas |
| US7893067B2 (en) | 2007-06-27 | 2011-02-22 | Medivir Ab | Cysteine protease inhibitors |
| EP2216047A4 (en) * | 2007-10-24 | 2011-12-28 | Nat Univ Corp Tokyo Med & Dent | Regulator for signaling of toll-like receptor, which comprises cathepsin inhibitor as active ingredient |
| WO2009076490A1 (en) * | 2007-12-12 | 2009-06-18 | Velcura Therapeutics, Inc. | Use of cathepsin l antagonists in the treatment of bone disease |
| EP2719700A1 (en) | 2008-01-09 | 2014-04-16 | Amura Therapeutics Limited | Tetrahydrofuro(3,2-b)pyrrol-3-one derivatives as inhibitors of cysteine proteinases |
| WO2009103432A2 (en) * | 2008-02-21 | 2009-08-27 | Sanofi-Aventis | Covalently binding imaging probes |
| GB0817425D0 (en) * | 2008-09-24 | 2008-10-29 | Medivir Ab | Protease inhibitors |
| US20100298507A1 (en) | 2009-05-19 | 2010-11-25 | Menschig Klaus R | Polyisobutylene Production Process With Improved Efficiencies And/Or For Forming Products Having Improved Characteristics And Polyisobutylene Products Produced Thereby |
| BR112013029672A2 (pt) | 2011-05-16 | 2017-01-17 | Bayer Ip Gmbh | uso de inibição da catepsina k para o tratamento e/ou profilaxia da hipertensão pulmonar e/ou insuficiência cardíaca |
| EP2537532A1 (en) | 2011-06-22 | 2012-12-26 | J. Stefan Institute | Cathepsin-binding compounds bound to a nanodevice and their diagnostic and therapeutic use |
| US9593138B2 (en) | 2012-10-05 | 2017-03-14 | Wayne State University | Nitrile-containing enzyme inhibitors and ruthenium complexes thereof |
| WO2014199644A1 (ja) | 2013-06-14 | 2014-12-18 | 生化学工業株式会社 | α－オキソアシルアミノカプロラクタム誘導体 |
| WO2014199645A1 (ja) | 2013-06-14 | 2014-12-18 | 生化学工業株式会社 | α－オキソアシルアミノカプロラクタム体 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3467691A (en) | 1964-04-22 | 1969-09-16 | Tsutomu Irikura | N-(n-acylaminoacyl)-aminoacetonitriles |
| US5206249A (en) | 1991-03-27 | 1993-04-27 | Du Pont Merck Pharmaceutical Company | Bis-naphthalimides containing amino-acid derived linkers as anticancer agents |
| EP0547699A1 (en) | 1991-12-19 | 1993-06-23 | Merck & Co. Inc. | Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme |
| JP3283114B2 (ja) | 1992-09-07 | 2002-05-20 | クミアイ化学工業株式会社 | 縮合ヘテロ環誘導体及び農園芸用殺菌剤 |
| JP2848232B2 (ja) | 1993-02-19 | 1999-01-20 | 武田薬品工業株式会社 | アルデヒド誘導体 |
| US5574064A (en) | 1993-04-28 | 1996-11-12 | Kumiai Chemical Industry Co., Ltd. | Amino-acid amide derivatives, agricultural or horticultural fungicides, and method for producing the same |
| WO1995003794A1 (en) * | 1993-07-30 | 1995-02-09 | Smithkline Beecham Corporation | 3-cyano-3-(3,4-disubstituted)phenylcyclohexyl-1-carboxylates |
| RU2126418C1 (ru) | 1993-11-01 | 1999-02-20 | Циба-Гейги Джапан Димитед | Антагонисты рецепторов эндотелина |
| US5486623A (en) * | 1993-12-08 | 1996-01-23 | Prototek, Inc. | Cysteine protease inhibitors containing heterocyclic leaving groups |
| IL112759A0 (en) * | 1994-02-25 | 1995-05-26 | Khepri Pharmaceuticals Inc | Novel cysteine protease inhibitors |
| ATE195933T1 (de) | 1994-03-10 | 2000-09-15 | Searle & Co | L-n6-(1-iminoethyl)lysin - derivate und ihre verwendung als no-synthase - inhibitoren |
| US5614649A (en) * | 1994-11-14 | 1997-03-25 | Cephalon, Inc. | Multicatalytic protease inhibitors |
| US5804560A (en) | 1995-01-06 | 1998-09-08 | Sibia Neurosciences, Inc. | Peptide and peptide analog protease inhibitors |
| AU5687396A (en) * | 1995-04-21 | 1996-11-07 | Novarits Ag | N-aroylamino acid amides as endothelin inhibitors |
| WO1997027200A1 (en) | 1996-01-26 | 1997-07-31 | Smithkline Beecham Plc | Thienoxazinone derivatives useful as antiviral agents |
| WO1998001133A1 (fr) | 1996-07-08 | 1998-01-15 | Yamanouchi Pharmaceutical Co., Ltd. | Inhibiteurs de la resorption osseuse |
| AU729133B2 (en) | 1996-11-22 | 2001-01-25 | Elan Pharmaceuticals, Inc. | N-(aryl/heteroaryl/alkylacetyl) amino acid amides, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds |
| GB9723407D0 (en) * | 1997-11-05 | 1998-01-07 | Ciba Geigy Ag | Organic compounds |
| AU751669B2 (en) | 1997-11-05 | 2002-08-22 | Novartis Ag | Dipeptide nitriles |
| US6355678B1 (en) * | 1998-06-29 | 2002-03-12 | Parker Hughes Institute | Inhibitors of the EGF-receptor tyrosine kinase and methods for their use |
| EP1155011A1 (en) | 1999-02-20 | 2001-11-21 | AstraZeneca AB | Di- and tripeptide nitrile derivatives as inhibitors of cathepsin l and cathepsin s |
| WO2000049007A1 (en) | 1999-02-20 | 2000-08-24 | Astrazeneca Ab | Acetamido acetonitrile derivatives as inhibitors of cathepsin l and/or cathepsin s |
| JP2002538151A (ja) | 1999-03-02 | 2002-11-12 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | カテプシンの可逆的インヒビターとして有用な化合物 |
| CZ20013248A3 (cs) | 1999-03-15 | 2002-04-17 | Axys Pharmaceuticals, Inc. | Nové sloučeniny a prostředky jako inhibitory proteázy |
| US6420364B1 (en) * | 1999-09-13 | 2002-07-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compound useful as reversible inhibitors of cysteine proteases |
| AU777472B2 (en) * | 1999-09-16 | 2004-10-21 | Axys Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions as cathepsin S inhibitors |
| JP2001139320A (ja) * | 1999-11-05 | 2001-05-22 | Asahi Glass Co Ltd | 球状シリカゲルの製造方法 |
| CA2395179A1 (en) * | 1999-12-24 | 2001-07-05 | F. Hoffmann-La Roche Ag | Nitrile derivatives as cathepsin k inhibitors |
| CA2396257A1 (en) * | 2000-01-06 | 2001-07-12 | Merck Frosst Canada & Co./Merck Frosst Canada & Cie | Novel compounds and compositions as protease inhibitors |
| GB0003111D0 (en) * | 2000-02-10 | 2000-03-29 | Novartis Ag | Organic compounds |
-
2000
- 2000-02-10 GB GBGB0003111.2A patent/GB0003111D0/en not_active Ceased
-
2001
- 2001-02-02 TW TW090102220A patent/TWI258473B/zh not_active IP Right Cessation
- 2001-02-06 MY MYPI20010514A patent/MY122826A/en unknown
- 2001-02-07 US US09/778,302 patent/US6642239B2/en not_active Expired - Fee Related
- 2001-02-08 CZ CZ20022721A patent/CZ20022721A3/cs unknown
- 2001-02-08 CN CNB018048099A patent/CN1183122C/zh not_active Expired - Fee Related
- 2001-02-08 HU HU0300148A patent/HUP0300148A3/hu unknown
- 2001-02-08 PE PE2001000139A patent/PE20020220A1/es not_active Application Discontinuation
- 2001-02-08 EP EP01919270A patent/EP1254124B1/en not_active Expired - Lifetime
- 2001-02-08 DE DE60135087T patent/DE60135087D1/de not_active Expired - Lifetime
- 2001-02-08 AR ARP010100563A patent/AR029466A1/es not_active Application Discontinuation
- 2001-02-08 TR TR2002/01752T patent/TR200201752T2/xx unknown
- 2001-02-08 WO PCT/EP2001/001359 patent/WO2001058886A1/en active IP Right Grant
- 2001-02-08 CA CA002396158A patent/CA2396158C/en not_active Expired - Fee Related
- 2001-02-08 BR BR0108118-7A patent/BR0108118A/pt not_active Application Discontinuation
- 2001-02-08 IL IL15040601A patent/IL150406A0/xx unknown
- 2001-02-08 AU AU46426/01A patent/AU764334B2/en not_active Ceased
- 2001-02-08 AT AT01919270T patent/ATE402930T1/de active
- 2001-02-08 ES ES01919270T patent/ES2310177T3/es not_active Expired - Lifetime
- 2001-02-08 MX MXPA02007768A patent/MXPA02007768A/es active IP Right Grant
- 2001-02-08 RU RU2002123350/04A patent/RU2265601C2/ru not_active IP Right Cessation
- 2001-02-08 PL PL357901A patent/PL200119B1/pl unknown
- 2001-02-08 SK SK1146-2002A patent/SK11462002A3/sk not_active Application Discontinuation
- 2001-02-08 KR KR1020027010280A patent/KR100544553B1/ko not_active Expired - Fee Related
- 2001-02-08 NZ NZ519940A patent/NZ519940A/en unknown
- 2001-02-08 CN CNA2004100909449A patent/CN1636980A/zh active Pending
- 2001-02-08 PT PT01919270T patent/PT1254124E/pt unknown
- 2001-02-08 JP JP2001558437A patent/JP3942895B2/ja not_active Expired - Fee Related
- 2001-02-08 RU RU2005108133/04A patent/RU2293732C2/ru active
- 2001-02-12 CO CO01010168A patent/CO5261578A1/es not_active Application Discontinuation
-
2002
- 2002-08-05 ZA ZA200206218A patent/ZA200206218B/en unknown
- 2002-08-09 NO NO20023780A patent/NO20023780D0/no unknown
-
2003
- 2003-04-09 US US10/410,377 patent/US20030203919A1/en not_active Abandoned
-
2005
- 2005-08-03 US US11/195,747 patent/US20050267129A1/en not_active Abandoned
-
2007
- 2007-04-23 US US11/738,878 patent/US20070191392A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20020220A1 (es) | Compuestos de nitrilo de dipeptido como inhibidores de catepsina k | |
| PE20040898A1 (es) | Nuevos compuestos derivados de pirimidina | |
| PE20020858A1 (es) | Indanil aminas aciladas | |
| PE20030856A1 (es) | Esteres hidroxamato del acido n-(4-fenilsustituido)-antranilico | |
| PE20030226A1 (es) | Compuestos arilicos sustituidos con quinuclidinas para el tratamiento de enfermedades | |
| DK1585739T3 (da) | Substituerede arylcyclopropylacetamider som glucokinaseaktivatorer | |
| PE20130325A1 (es) | Derivados de piperidina, piperazina o tetrahidropiridilo como antagonistas de trpv1 | |
| DK1814846T3 (da) | 11beta-HSD1-inhibitorer | |
| PE20030968A1 (es) | Derivados de 5-feniltiazol como inhibidores de cinasas | |
| PL1996180T3 (pl) | Pochodne benzamidu i pirydyloamidu jako czynniki antybakteryjne | |
| PE20080077A1 (es) | Derivados de sulfonilfenilo como antagonistas del receptor de il-8 | |
| PE20061490A1 (es) | Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1 | |
| PE20020467A1 (es) | Compuestos de 1,4-dihidropiridina como antagonistas de bradicinina | |
| PE20040667A1 (es) | Derivados de cinamida | |
| PE20030925A1 (es) | Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico | |
| PE20061446A1 (es) | Compuestos de bencimidazol-carboxamida como agonistas de receptores 5-ht4 | |
| PE20040558A1 (es) | Derivados de fluorobenzamidas como inhibidores selectivos de la monoamino oxidasa b | |
| AR029343A1 (es) | USO DE UN ANTAGONISTA DE NMDA DE BAJA AFINIDAD PARA EL TRATAMIENTO DE LA DEPRESIoN | |
| CO5611136A2 (es) | Derivados de 4-(fenil-(piperidin-4-iliden-metil)-benzamida y su uso para el tratramiento del dolor, ansiedad o desordenes gastrointestinales | |
| AR023369A1 (es) | Secretagogos de la hormona del crecimiento | |
| PE20021003A1 (es) | Fenil-heterociclil-eteres como inhibidores selectivos de la recaptacion de serotonina (ssri) | |
| PE20050329A1 (es) | Derivados de nicotinamida como inhibidores de fosfodiesterasa pde4 | |
| HRP20070286T3 (en) | Substituted diketopiperazines and their use as oxytocyn antagonists | |
| NO20045063L (no) | Preparater inneholdende minst ett diformat | |
| PE20010300A1 (es) | Preparacion de piperidin-4-onas sustituidas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal | ||
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |